The PREVENT Risk Equations and Cardiovascular Prevention in East Asia
Abstract
Cardiovascular disease remains a leading cause of morbidity and mortality in East Asia, although its epidemiological profile differs substantially from that of Western populations. As East Asia experiences rapid increases in chronic kidney disease, diabetes, multimorbidity, and heart failure driven by population aging, accurate cardiovascular risk prediction has become increasingly important for the risk-stratified prevention of these diseases. Traditional risk prediction models, including the Framingham Risk Score, Pooled Cohort Equations, and SCORE, were derived largely from Western populations and often overestimated the risk in East Asian cohorts without recalibration. In 2025, the American Heart Association introduced the PREVENT equations to estimate 10-year and 30-year risks of total cardiovascular disease, atherosclerotic cardiovascular disease, and heart failure within an integrated cardiovascular-kidney-metabolic framework. Given the growing globalization of cardiovascular prevention and international clinical research, understanding whether PREVENT performs well in East Asian populations has important implications for the clinical implementation and harmonization of risk assessment frameworks. This review summarizes the evolution of cardiovascular risk prediction, key innovations of PREVENT, and emerging validation evidence from East Asia. Early studies from Korea and China suggest the reasonable transportability of these approaches. However, evidence from Japan remains limited, and further validation and recalibration are warranted. We also discuss the challenges related to heart failure prediction, add-on variables, electronic health record data infrastructure, and AI-assisted risk assessment.
Related
- Preeclampsia prevention by risk-stratified timed birth: a post-hoc Bayesian analysis of the PREVENT-PE randomised trial
- Lipoprotein(a) as a cardiovascular risk accelerator in primary prevention: Age-equivalent risk and event-free survival at 10 years in the UK biobank
- Clinically Accessible Phenotypes Refine Cardiovascular Risk Stratification Beyond Contemporary Clinical Equations
- Multidisciplinary evaluation of Polygenic Risk Score and Digital Health in Cardiovascular Prevention
- Health behavior profiles and potential support needs among community residents with clustered cardiovascular risk factors: a latent profile and explainable machine learning analysis for community-based prevention
BibTeX
@article{sawano2026prevent,
title = {{The PREVENT Risk Equations and Cardiovascular Prevention in East Asia}},
author = {Mitsuaki Sawano and Kentaro Ejiri and Yuichiro Mori and Hokyou Lee and Aya Hirata and Kosuke Inoue and Takeshi Kitai and Shun Kohsaka and Hyeon Chang Kim and Kunihiro Matsushita},
journal = {Journal of Atherosclerosis and Thrombosis},
year = {2026},
month = oct,
doi = {10.5551/jat.rv22056},
url = {https://www.jstage.jst.go.jp/article/jat/33/10/33_RV22056/_article},
note = {CC BY-NC-SA},
}
RIS
TY - JOUR
TI - The PREVENT Risk Equations and Cardiovascular Prevention in East Asia
AU - Mitsuaki Sawano
AU - Kentaro Ejiri
AU - Yuichiro Mori
AU - Hokyou Lee
AU - Aya Hirata
AU - Kosuke Inoue
AU - Takeshi Kitai
AU - Shun Kohsaka
AU - Hyeon Chang Kim
AU - Kunihiro Matsushita
PY - 2026
DA - 2026/10/01
JO - Journal of Atherosclerosis and Thrombosis
DO - 10.5551/jat.rv22056
UR - https://www.jstage.jst.go.jp/article/jat/33/10/33_RV22056/_article
AB - Cardiovascular disease remains a leading cause of morbidity and mortality in East Asia, although its epidemiological profile differs substantially from that of Western populations. As East Asia experiences rapid increases in chronic kidney disease, diabetes, multimorbidity, and heart failure driven by population aging, accurate cardiovascular risk prediction has become increasingly important for the risk-stratified prevention of these diseases. Traditional risk prediction models, including the Framingham Risk Score, Pooled Cohort Equations, and SCORE, were derived largely from Western populations and often overestimated the risk in East Asian cohorts without recalibration. In 2025, the American Heart Association introduced the PREVENT equations to estimate 10-year and 30-year risks of total cardiovascular disease, atherosclerotic cardiovascular disease, and heart failure within an integrated cardiovascular-kidney-metabolic framework. Given the growing globalization of cardiovascular prevention and international clinical research, understanding whether PREVENT performs well in East Asian populations has important implications for the clinical implementation and harmonization of risk assessment frameworks. This review summarizes the evolution of cardiovascular risk prediction, key innovations of PREVENT, and emerging validation evidence from East Asia. Early studies from Korea and China suggest the reasonable transportability of these approaches. However, evidence from Japan remains limited, and further validation and recalibration are warranted. We also discuss the challenges related to heart failure prediction, add-on variables, electronic health record data infrastructure, and AI-assisted risk assessment.
SN - 1880-3873
SN - 1340-3478
ER -